X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
A MALT1 inhibitor, RHX-317 is designed to inhibit the activity of multiple immune cell types, attenuating the inflammatory response in the activated immune system, for the treatment of autoimmune and inflammatory diseases.
Lead Product(s): RHX-317
Therapeutic Area: Immunology Product Name: RHX-317
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
RHX-317 targets MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1), a protein expressed exclusively in cells of immune system, designed to inhibit activity of multiple immune cell types, attenuating the inflammatory response in activated immune system.
Lead Product(s): RHX-317
Therapeutic Area: Immunology Product Name: RHX-317
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
RHX-317, is a novel, small molecule MALT1 inhibitor initially in development for the treatment of chronic GVHD. Preclinical data demonstrate MALT1 inhibition targets pathogenic activity of the activated immune system, showing efficacy in a model of cGVHD.
Lead Product(s): RHX-317
Therapeutic Area: Immunology Product Name: RHX-317
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2021
Details:
Rheos Medicines will present preclinical data showing the potential of RHX-317, a MALT1 inhibitors for the treatment of chronic Graft-Versus-Host Disease (GVHD) at the 63rd Annual Meeting of the American Society of Hematology.
Lead Product(s): RHX-317
Therapeutic Area: Immunology Product Name: RHX-317
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2021
Details:
The results demonstrating MALT1 inhibition support Rheos’s lead product candidate, RHX-317, a novel, small molecule MALT1 inhibitor, that the company is initially developing for the treatment of chronic graft versus host disease (GVHD).
Lead Product(s): RHX-317
Therapeutic Area: Immunology Product Name: RHX-317
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2021
Details:
The goal of the collaboration is to provide biological resources from HSC patients in order to evaluate MALT1-targeted therapeutics, including Rheos’s lead product candidate, RHX-317, for Graft-versus-Host Disease, based on functional immunologic profiling of patients.
Lead Product(s): RHX-317
Therapeutic Area: Immunology Product Name: RHX-317
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Cryostem
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 27, 2021
Details:
The patent application is an outcome of the option agreement that was previously entered into between the two companies regarding Medivir’s preclinical MALT1 project.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Medivir
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
